Skip to main content
AmigoFish

Rapid Fire Rounds - Multiple Myeloma Management with Dr. Joseph Mikhael

From Oncology Brothers: Practice-Changing Cancer Discussions · · 25 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

Welcome to the Oncology Brothers podcast and our new series, Rapid Fire Rounds! In this episode, we were joined by Dr. Joseph Mikhael, a myeloma specialist from the City of Hope, to answer 10–12 community-sourced questions on multiple myeloma management.

The panel covers:

- Frontline therapy: Quadruplet therapy, carfilzomib vs bortezomib, and high-risk disease definitions

- Maintenance strategies: Lenalidomide alone vs daratumumab-lenalidomide vs carfilzomib-lenalidomide, with insights from the ENDURANCE, ATLAS trials

- Relapsed/refractory disease: Sequencing CAR T-cell therapy, bispecific antibodies (teclistamab + daratumumab), and the newly approved cereblon modulators (CELMoDs) like mezigdomide

- CAR-T logistics: The critical distinction between holding therapy (pre-collection) and bridging therapy (post-collection)

- Supportive care: IVIG, antiviral/antifungal prophylaxis, and monitoring for ICANS

- MRD testing: Current role in clinical practice and its use as an endpoint for drug approval

This episode is packed with practical, actionable insights for community oncologists managing myeloma day-to-day.

Listen us on:

Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o

Follow us on social media:

- ⁠X/Twitter: https://x.com/oncbrothers

- ⁠Instagram: https://www.instagram.com/oncbrothers

- Website: https://oncbrothers.com/

Don't forget to like, subscribe, and hit the notification bell for more Rapid Fire Rounds from the Oncology Brothers!

#MultipleMyeloma, #CARTtherapy, #MRD, #CELMoD, #OncologyBrothers

Back to Oncology Brothers: Practice-Changing Cancer Discussions · Report a problem